Geode Capital Management LLC Grows Stock Holdings in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)

Geode Capital Management LLC grew its holdings in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) by 259.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 238,737 shares of the company’s stock after buying an additional 172,382 shares during the period. Geode Capital Management LLC owned approximately 0.81% of Telomir Pharmaceuticals worth $1,533,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. State Street Corp raised its holdings in Telomir Pharmaceuticals by 99.1% during the 3rd quarter. State Street Corp now owns 36,094 shares of the company’s stock valued at $232,000 after buying an additional 17,967 shares during the period. Beaird Harris Wealth Management LLC increased its position in Telomir Pharmaceuticals by 212.9% during the second quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock valued at $70,000 after acquiring an additional 9,950 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Telomir Pharmaceuticals in the second quarter valued at $241,000. Suncoast Equity Management lifted its holdings in shares of Telomir Pharmaceuticals by 109.9% in the 3rd quarter. Suncoast Equity Management now owns 51,194 shares of the company’s stock worth $329,000 after acquiring an additional 26,803 shares during the last quarter. Finally, Barclays PLC boosted its stake in shares of Telomir Pharmaceuticals by 325.1% during the 3rd quarter. Barclays PLC now owns 7,018 shares of the company’s stock worth $45,000 after purchasing an additional 5,367 shares during the period.

Telomir Pharmaceuticals Trading Down 5.5 %

Shares of NASDAQ:TELO opened at $4.30 on Thursday. Telomir Pharmaceuticals, Inc. has a 12 month low of $3.11 and a 12 month high of $20.72. The firm’s 50-day moving average is $4.57 and its 200 day moving average is $4.76.

Telomir Pharmaceuticals Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.